[1]谈玖婷,傅聿明,刘 婧,等.甲状腺癌组织中DCBLD2 和MAP4K3 的表达及与临床病理特征及预后的关系[J].现代检验医学杂志,2024,39(02):34-38+67.[doi:10.3969/j.issn.1671-7414.2024.02.007]
　TAN Jiuting,FU Yuming,LIU Jing,et al.Expression of DCBLD2 and MAP4K3 in Thyroid Cancer Tissue and Their Relationship with Clinico-pathological Features and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(02):34-38+67.[doi:10.3969/j.issn.1671-7414.2024.02.007]
点击复制

甲状腺癌组织中DCBLD2 和MAP4K3 的表达及与临床病理特征及预后的关系()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年02期
页码:
34-38+67
栏目:
论著
出版日期:
2024-03-31

文章信息/Info

Title:
Expression of DCBLD2 and MAP4K3 in Thyroid Cancer Tissue and Their Relationship with Clinico-pathological Features and Prognosis
文章编号:
1671-7414（2024）02-034-06
作者:
谈玖婷; 傅聿明; 刘 婧; 张倜然
（扬州大学附属兴化市人民医院，江苏兴化 225700）
Author(s):
TAN Jiuting;  FU Yuming;  LIU Jing;  ZHANG Tiran
（Xinghua People’s Hospital Affiliated to Yangzhou University, Jiangsu Xinghua 225700, China）
关键词:
甲状腺癌; 盘状蛋白含CUB 和LCCL 结构域2; 丝裂原活化蛋白激酶激酶激酶激酶3; 无进展生存预后
分类号:
R736.1；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.02.007
文献标志码:
A
摘要:
目的 探讨甲状腺癌组织中盘状蛋白含CUB 和LCCL 结构域2（discoidin CUB and LCCL domain containing 2，DCBLD2）、丝裂原活化蛋白激酶激酶激酶激酶3（mitogen-activated protein kinase kinase kinase kinase 3，MAP4K3）的表达及与临床病理特征及预后的关系。方法 选取2016 年1 月～ 2020 年6 月在扬州大学附属兴化市人民医院诊治的92 例甲状腺癌患者。采用免疫组织化学（immunohitochemistry, IHC）检测癌组织及癌旁组织中DCBLD2 和MAP4K3的表达。比较不同临床病理特征甲状腺癌患者DCBLD2 和MAP4K3 表达差异。Kaplan-Meier 曲线分析不同DCBLD2和MAP4K3 表达患者无进展生存预后的差异。多因素COX 分析影响甲状腺癌无进展生存预后的危险因素。结果 甲状腺癌组织中DCBLD2（67.39%），MAP4K3（65.22%）阳性率高于癌旁组织（5.43%，6.52%），差异具有统计学意义（χ2=76.262，68.894，均P ＜ 0.05）。癌组织中DCBLD2 与MAP4K3 的表达呈显著正相关（r=0.742，P ＜ 0.05）。TNM 分期III ～ IV 期、并发淋巴结转移癌组织中DCBLD2 的阳性率（87.18%，93.75%）和MAP4K3 的阳性率（84.62%，90.63%）分别高于I ～ II 期（52.83%，50.94%）、无淋巴结转移癌组织（53.33%，51.67%），差异具有统计学意义（χ2=11.230 ～ 15.513，均P<0.05）。DCBLD2 阳性和阴性组患者三年无进展生存率分别为74.19%（46/62），93.33%（28/30）。MAP4K3 阳性和阴性组患者三年无进展生存率分别为75.00%（45/60），90.63%（29/32）。DCBLD2 阳性组，MAP4K3 阳性组患者三年累积无进展生存率低于DCBLD2 阴性组、MAP4K3 阴性组，差异具有统计学意义（χ2=4.533，4.138，P=0.033，0.046）。DCBLD2 阳性（OR=1.659，P=0.001）、MAP4K3 阳性（OR=1.606，P=0.001）、肿瘤TNM分期Ⅲ～Ⅳ期（OR=1.766，P=0.001）和并发淋巴结转移（OR=1.868，P=0.001）是影响甲状腺癌患者无进展生存预后的独立危险因素。结论 甲状腺癌组织中DCBLD2 和MAP4K3 表达升高，两者均参与甲状腺癌的发生发展，有助于评估甲状腺癌患者的无进展生存预后。
Abstract:
Objective To investigate the expression of discoidin CUB and LCCL domain containing 2 (DCBLD2) and mitogen activated protein kinase kinase kinase kinase 3 (MAP4K3) in thyroid cancer and their relationship with clinico-pathological features and prognosis. Methods A total of 92 patients with thyroid cancer diagnosed and treated in Xinghua People’s Hospital Affiliated to Yangzhou University from January 2016 to June 2020 were selected. Immunohistochemistry (IHC) was used to detect the expression of DCBLD2 and MAP4K3 in thyroid cancer tissues and adjacent tissues. The expression differences of DCBLD2 and MAP4K3 in thyroid cancer patients with different clinicopathological features were compared. Kaplan-Meier curve analysis was used to analyze differences in the progression-free survival prognosis of patients with different DCBLD2 and MAP4K3 expressions. Multivariate COX analysis was used to analyze the risk factors affecting the progression-free survival prognosis of thyroid cancer. Results The positive rates of DCBLD2 (67.39%) and MAP4K3 (65.22%) in thyroid cancer tissues were higher than those in adjacent tissues (5.43%, 6.52%), and the differences were statistically significant (χ2=76.262, 68.894, all P < 0.05). The expression of DCBLD2 was positively correlated with MAP4K3 (r=0.742, P < 0.001). The positive rates of DCBLD2 and MAP4K3 in stage III~IV(87.18%, 84.62%) and lymph node metastatic cancer tissues(93.75%, 90.63%) were higher than those in stage I~II (52.83%, 50.94%) and non lymph node metastatic cancer tissues(53.33%, 51.67%), with statistically significant differences (χ2=11.230 ～ 15.513, all P<0.05). The 3-year progression-free survival rates of DCBLD2- positive and DCBLD2-negative patients were 74.19% (46/62) and 93.33% (28/30), respectively. The 3-year progression-free survival rates of MAP4K3 positive and negative patients were 75.00% (45/60) and 90.63% (29/32), respectively. The 3-year cumulative progression-free survival rate of DCBLD2 positive group and MAP4K3 positive group was lower than that of DCBLD2 negative group and MAP4K3 negative group, and the differences were statistically significant (χ2=4.533, 4.138, P=0.033, 0.046). DCBLD2 positive (OR=1.659, P=0.001), MAP4K3 positive (OR=1.606, P=0.001), tumor TNM stage III~IV (OR=1.766, P=0.001) and combined lymph node metastasis (OR=1.868, P=0.001) were independent risk factors for the progression-free survival prognosis of thyroid cancer patients. Conclusion The expressions of DCBLD2 and MAP4K3 were increased in thyroid cancer tissue. They are involved in the occurrence and development of thyroid cancer, which may help evaluate the progression-free survival prognosis of thyroid cancer patients.

参考文献/References:

[1] SEIB C D, SOSA J A. Evolving understanding of the epidemiology of thyroid cancer[J]. Endocrinology and Metabolism Clinics of North America, 2019, 48(1): 23-35.
[2] 王永斌, 邓智勇, 肖世闻, 等. 分化型甲状腺癌术后抑制状态下血清甲状腺球蛋白水平检测的临床诊断价值[J]. 现代检验医学杂志, 2019, 34(5): 133-134, 138. WANG Yongbin, DENG Zhiyong, XIAO Shiwen, et al. Clinical value of serumnon-stimulated thyroglobulin(nstg) in differentiated thyroid cancer (DTC) patients in after thyroidectomy[J]. Journal of Modern Laboratory Medicine, 2019, 34(5): 133-134, 138.
[3] MAIUTHED A, PRAKHONGCHEEP O ,CHANVORACHOTE P. Microarray-based analysis of genes, transcription factors, and epigenetic modifications in lung cancer exposed to nitric oxide[J].Cancer Genomics & Proteomics, 2020, 17(4): 401-415.
[4] HE Jie, HUANG Hongli, DU Yanlei, et al. Association of DCBLD2 upregulation with tumor progression and poor survival in colorectal cancer[J]. Cellular Oncology (Dordrecht), 2020, 43(3): 409-420.
[5] CHUANG H C, CHANG C C, TENG C F, et al. MAP4K3/GLK promotes lung cancer metastasis by phosphorylating and activating IQGAP1[J]. Cancer Research, 2019, 79(19): 4978-4993.
[6] CHUANG H C, TAN T H. MAP4K3/GLK in autoimmune disease, cancer and aging[J]. Journal of Biomedical Science, 2019, 26(1): 82.
[7] 张新洲, 刘劲松, 许娴, 等. 2005~2016 年中国甲状腺癌发病和死亡趋势分析[J]. 中华肿瘤防治杂志,2022, 29(24): 1725-1733. ZHANG Xinzhou, LIU Jinsong, XU Xian, et al. Trends of thyroid cancer incidence and mortality in China from 2005 to 2016[J]. Chinese Journal of Cancer Prevention and Treatment, 2022, 29(24): 1725-1733.
[8] 徐志勇, 马晓良. 甲状腺癌患者术后复发风险预测的列线图模型建立[J]. 实用肿瘤学杂志, 2021,35(1): 35-40. XU Zhiyong, MA Xiaoliang. Establishment of a nomogram model for predicting the risk of postoperative recurrence in patients with thyroid cancer[J]. Practical Oncology Journal,2021, 35(1): 35-40.
[9] DONG Yang, MA Weiming, SHI Zhenduo, et al. Role of NRP1 in bladder cancer pathogenesis and progression[J]. Frontiers in Oncology, 2021, 11: 685980.
[10] XIE Pan, LIU Junyan, YAN Han, et al. Pancancer analyses identify DCBLD2 as an oncogenic,immunological, and prognostic biomarker[J]. Frontiers in Pharmacology, 2022, 13: 950831.
[11] FENG Zengyu, LI Kexian, WU Yulian, et al. Transcriptomic profiling identifies DCBLD2 as a diagnostic and prognostic biomarker in pancreatic ductal adenocarcinoma[J]. Frontiers in Molecular Biosciences, 2021, 8: 659168.
[12] TAN Jiuting, LI Chunpu, REN Lijue, et al. MiR-451a suppresses papillary thyroid cancer cell proliferation and invasion and facilitates apoptosis through targeting DCBLD2 and AKT1[J]. Molecular and Cellular Probes,2022, 66: 101863.
[13] CHEN Xiaosu, L? Yajing, XU Kejia, et al. DCBLD2 mediates epithelial-mesenchymal transition-induced metastasis by cisplatin in lung adenocarcinoma[J].Cancers, 2021, 13(6): 1403.
[14] CHEN Hualin, YANG Wenjie, LI Yingjie, et al. Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients[J]. Frontiers in Immunology, 2023, 14:1198878.
[15] HSU C L, LEE E X, GORDON K L, et al. MAP4K3 mediates amino acid-dependent regulation of autophagy via phosphorylation of TFEB[J]. Nature Communications, 2018, 9(1): 942.
[16] CHUANG H C, HSUEH C H, HSU P M, et al. SARSCoV-2 spike protein enhances MAP4K3/GLK-induced ACE2 stability in COVID-19[J]. EMBO Molecular Medicine, 2022, 14(9): 15904-15914.
[17] WANG Ziquan, HAN Zhengxiang, ZHANG Lansheng,et al. MicroRNA-98-5p regulates the proliferation and apoptosis of A549 cells by targeting MAP4K3[J].Oncology Letters, 2019, 18(4): 4288-4293.
[18] ZHUANG Qingyang, HUANG Zhangzhou, ZHUANG Wu, et al. Knockdown of circ-RAD23B inhibits nonsmall cell lung cancer progression via the miR-142-3p/MAP4K3 axis[J]. Thoracic Cancer, 2022, 13(5): 750-760.
[19] BRANCH M R, HSU C L, OHNISHI K,et al. MAP4K3 inhibits sirtuin-1 to repress the LKB1-AMPK pathway to promote amino acid-dependent activation of the mTORC1 complex[J]. Life Science Alliance, 2023,6(8): e202201525.
[20] LIU Fangzhou, YIN Rong, CHEN Xinyuan, et al. Over-expression of miR-206 decreases the euthyroxresistance by targeting MAP4K3 in papillary thyroid carcinoma[J]. Biomedecine & Pharmacotherapie, 2019,114: 108605.

相似文献/References:

[1]彭继英a,杨红杰b,石晓欣a,等.细针穿刺细胞学检查在甲状腺癌碘-131 治疗后复发诊断中的应用价值[J].现代检验医学杂志,2020,35(01):127.[doi:10.3969/j.issn.1671-7414.2020.01.033]
　PENG Ji-yinga,YANG Hong-jieb,SHI Xiao-xina,et al.Application Value of Fine Needle Aspiration Cytology in Recurrence Diagnosis of Thyroid Cancer after Iodine-131 Treatment[J].Journal of Modern Laboratory Medicine,2020,35(02):127.[doi:10.3969/j.issn.1671-7414.2020.01.033]
[2]赵芳芳,郭　红,陈　嘉.LncRNA TUG1 在甲状腺癌组织中的表达及其对细胞增殖和迁移的影响[J].现代检验医学杂志,2020,35(06):42.[doi:doi:10.3969/j.issn.1671-7414.2020.06.011]
　ZHAO Fang-fang,GUO Hong,CHEN Jia.Expression of LncRNA TUG1 in Thyroid Carcinoma Tissues and Its Effect onCell Proliferation and Migration[J].Journal of Modern Laboratory Medicine,2020,35(02):42.[doi:doi:10.3969/j.issn.1671-7414.2020.06.011]
[3]仲亚东,孔德桐,马伯敏.甲状腺癌患者组织及手术前后血清中NR3C2 和ZEB1 表达水平及其与预后价值研究[J].现代检验医学杂志,2023,38(04):94.[doi:10.3969/j.issn.1671-7414.2023.04.017]
　ZHONG Yadong,KONG Detong,MA Bomin.Study on the Expression Level of NR3C2 and ZEB1 in Thyroid Cancer Tissue and Serum of Patients before and after Surgery and Their Prognostic Value[J].Journal of Modern Laboratory Medicine,2023,38(02):94.[doi:10.3969/j.issn.1671-7414.2023.04.017]

备注/Memo

备注/Memo:
基金项目： 江苏省非编码RNA 基础与临床转化重点实验室课题项目（202113）：miR-451a 通过PI3K/AKI/VEGF 信号通路参与调控甲状腺细胞增殖的分子机制研究。
作者简介： 谈玖婷（1988-），女，硕士，主治医师，研究方向：垂体疾病、糖尿病、甲状腺疾病的诊疗，E-mail：tangjiuting68453@126.com。
更新日期/Last Update: 2024-03-15